How does this company make money?
When a lab first buys an instrument — a NovaSeq, MiSeq, or NextSeq — the company collects a one-time payment for that capital equipment. From that point on, every sequencing experiment the lab runs consumes a reagent kit and a flow cell, both of which must be repurchased each time. Those per-run sales continue for as long as the instrument is in use. The company also sells service contracts that cover instrument maintenance and software updates.
What makes this company hard to replace?
A clinical lab that has validated a diagnostic test — such as a prenatal screening test — on one sequencing platform must run a full revalidation study, lasting 6 to 12 months, before it can legally use a different platform for that test. Beyond the regulatory hurdle, the software pipelines labs use to analyze sequencing data are calibrated to the specific error patterns and quality signals of the platform they were built on, and those calibrations do not transfer to a different technology. Lab staff also require platform-specific training on how to handle reagents and run quality checks, adding further cost and time to any switch.
What limits this company?
Every flow cell has to be individually patterned using ASML photolithography equipment inside semiconductor-grade cleanrooms in San Diego and Singapore. That patterning step cannot simply be sped up by adding more workers — it is constrained by the physical capacity of those cleanrooms. The total number of DNA sequencing runs that labs around the world can perform is ultimately capped by how many flow cells those two facilities can produce.
What does this company depend on?
The company cannot operate without ASML photolithography equipment to pattern flow cells, fluorescent nucleotide analogs built around its proprietary reversible terminator chemistry, CCD imaging sensors calibrated to specific fluorophore wavelengths, semiconductor-grade cleanroom facilities in San Diego and Singapore, and FDA 510(k) clearances that allow its instruments to be used in clinical diagnostic settings.
Who depends on this company?
Clinical laboratories running NIPT programs — prenatal tests that screen for chromosomal conditions — would lose their screening capacity if sequencing reagents became unavailable. Pharmaceutical companies conducting genomic clinical trials would face delays to their research protocols if the sequencing platforms went offline. Population genomics projects like UK Biobank, which sequences hundreds of thousands of people's genomes to study disease, would lose the ability to process new samples without compatible sequencing chemistry.
How does this company scale?
Once a reagent kit formulation is established, producing more kits is relatively straightforward — automated liquid handling and packaging lines can run at high volume without much added complexity. Flow cells are the hard part: each one requires individual photolithographic patterning and surface chemistry treatment inside the cleanrooms in San Diego and Singapore, and that process cannot be meaningfully accelerated beyond the physical limits of those facilities. Reagent revenue can grow quickly; flow cell production cannot keep pace at the same rate.
What external forces can significantly affect this company?
CFIUS, the US government body that reviews foreign investments for national security risks, can block acquisitions or technology transfers involving genomics companies because DNA sequencing has potential military and intelligence applications. European GDPR rules and emerging genetic privacy laws in other countries restrict how genomic data can be moved across borders, limiting the company's ability to support large international sequencing projects. Disruptions to semiconductor supply chains, particularly those involving Taiwan, can affect the availability of CCD sensors that the optical detection systems rely on.
Where is this company structurally vulnerable?
If the reversible terminator chemistry or the flow cell surface preparation drifts out of specification — through a contamination event, a formulation error, or a failure of the ASML photolithography equipment used to pattern the flow cells — sequencing errors would spread across every instrument in the field running that batch of reagents. Because all three components are so tightly matched, fixing the problem means requalifying the entire system from scratch, not just replacing one part. During that period, clinical labs running prenatal screening programs and pharmaceutical companies running genomic trials could not simply switch to another platform without triggering the same 6 to 12 month revalidation process.
CompanyGraph